Literature DB >> 10984639

Inhibition of the amygdala and hippocampal calcium/calmodulin-dependent protein kinase II attenuates the dependence and relapse to morphine differently in rats.

L Lu1, S Zeng, D Liu, X Ceng.   

Abstract

Learning and memory have been suggested to play an important role in the development of opiate addiction. Based on the recent finding that calcium/calmodulin protein kinase II (CaMKII) is essential in learning and memory processes, the present study was performed to examine whether inhibition of hippocampal and amygdala CaMKII prevents the dependence and relapse to morphine. The results showed that inhibition of CaMKII by microinjection of specific inhibitors KN-62 into hippocampus decreased the morphine withdrawal syndromes induced by opiate antagonist naloxone. In contrast, inhibition of CaMKII in amygdala failed to do so. Microinjection of KN-62 into both hippocampus and amygdala suppressed the development of formation and reactivation of morphine conditioned place preference (CPP). However, inhibition of CaMKII in amygdala, but not in hippocampus, could attenuate the maintenance of morphine CPP. These results suggest that hippocampal CaMKII is critically involved in the development of morphine physical and psychological dependence, and amygdala CaMKII is some different from hippocampal CaMKII in regulating the dependence and relapse to opiates. Inhibition of this kinase may have some therapeutic benefit in the treatment of opiate dependence and relapse.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984639     DOI: 10.1016/s0304-3940(00)01352-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  24 in total

Review 1.  The reinstatement model of drug relapse: history, methodology and major findings.

Authors:  Yavin Shaham; Uri Shalev; Lin Lu; Harriet de Wit; Jane Stewart
Journal:  Psychopharmacology (Berl)       Date:  2002-10-26       Impact factor: 4.530

2.  Delta opioid receptors colocalize with corticotropin releasing factor in hippocampal interneurons.

Authors:  T J Williams; T A Milner
Journal:  Neuroscience       Date:  2011-01-26       Impact factor: 3.590

3.  Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice.

Authors:  Anna Castañé; Rafael Maldonado; Olga Valverde
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

4.  Opiate exposure and withdrawal induces a molecular memory switch in the basolateral amygdala between ERK1/2 and CaMKIIα-dependent signaling substrates.

Authors:  Danika Lyons; Xavier de Jaeger; Laura G Rosen; Tasha Ahmad; Nicole M Lauzon; Jordan Zunder; Lique M Coolen; Walter Rushlow; Steven R Laviolette
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

5.  Differential modulation of drug-induced structural and functional plasticity of dendritic spines.

Authors:  Eric C Miller; Lei Zhang; Benjamin W Dummer; Desmond R Cariveau; Horace Loh; Ping-Yee Law; Dezhi Liao
Journal:  Mol Pharmacol       Date:  2012-05-17       Impact factor: 4.436

6.  Chronic, but not acute morphine treatment, up-regulates alpha-Ca2+/calmodulin dependent protein kinase II gene expression in rat brain.

Authors:  Yuejun Chen; Yan Jiang; Wen Yue; Yuqing Zhou; Lin Lu; Lan Ma
Journal:  Neurochem Res       Date:  2008-04-12       Impact factor: 3.996

Review 7.  Protein kinases and addiction.

Authors:  Anna M Lee; Robert O Messing
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

8.  Opiate Exposure State Controls a D2-CaMKIIα-Dependent Memory Switch in the Amygdala-Prefrontal Cortical Circuit.

Authors:  Laura G Rosen; Jordan Zunder; Justine Renard; Jennifer Fu; Walter Rushlow; Steven R Laviolette
Journal:  Neuropsychopharmacology       Date:  2015-07-15       Impact factor: 7.853

9.  Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling.

Authors:  Pilar Sánchez-Blázquez; María Rodríguez-Muñoz; Javier Garzón
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

10.  Targeted mutation of EphB1 receptor prevents development of neuropathic hyperalgesia and physical dependence on morphine in mice.

Authors:  Yuan Han; Xue-Song Song; Wen-Tao Liu; Mark Henkemeyer; Xue-Jun Song
Journal:  Mol Pain       Date:  2008-11-21       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.